Synonyms: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]BK | Firazyr® | HOE 140 | HOE140
icatibant is an approved drug (EMA (2008), FDA (2011))
Compound class:
Peptide
Comment: Synthetic analogue of bradykinin. There is some ambiguity in the literature and on online resources as to the exact chemical structure and stereochemistry of icatibant.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Immunopharmacology Comments |
Although not approved for inflammation we have included icatibant in GtoImmuPdb as it was evaluated as a potential disease modifying agent in patients with osteoarthritis (OA) in Phase 2 clinical trial NCT00303056. However, development has not progressed, and no trial results appear to have been published. The rationale for testing a B2 receptor antagonist in OA is discussed in [6]. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Hereditary angioedema |
Disease Ontology:
DOID:14735 OMIM: 106100, 610618 |
Approved drug for HAE. |